[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-natal-depression\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-natal-depression":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100656281","phase-3-brexanolone-lifting-outcomes-of-moms-100656281",false,"NCT07822321","Brexanolone Lifting Outcomes Of Moms","A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral LPCN 1154A in Women With Postpartum Depression","BLOOM","Key Inclusion Criteria:\n\n* Are female between 15 and 45 years of age, inclusive;\n* Have had a depressive episode that began no earlier than second trimester and no later than the first 4 weeks following delivery\n* Are \\\u003C 18 months postpartum at Screening\n* Hamilton Depression Rating Scale (HAM-D) 17-item score indicative of severe depression\n\nKey Exclusion Criteria:\n\n* Have a history of bipolar disorder, schizophrenia or schizoaffective disorder\n* Are currently experiencing active psychosis per Investigator assessment\n* Have a history of suicidal behavior associated with the current depressive episode\n* Have a history of seizure within six months of Screening","FEMALE","15 Years","45 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine:\n\n* If LPCN 1154A reduces depressive symptoms in subjects with severe PPD\n* How well LPCN 1154A is tolerated and what side effects it may cause",[28,29,30,31,32,33],"Depression, Postpartum","Postpartum Depression (PPD)","Post-partum Depression","Postnatal Depression","Post-Natal Depression","Peripartum Depression",[35,36,37,38,39,40,41],"Postpartum Depression","PPD","Depression","LPCN 1154A","brexanolone","neuroactive steriod","GABAA","RECRUITING","2026-09-10",{"date":45,"type":46},"2026-09-16","ACTUAL",{"date":48,"type":22},"2026-09",{"date":50,"type":22},"2027-09",{"name":52,"class":53},"Lipocine Inc.","INDUSTRY",16]